SCHEMBL12376015

SCHEMBL12376015

CCCCCc1ccc(-c2ccc3c(c2F)C(=O)OC(C2CCC(CCC)CC2)C3)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARB P10826 3/20 0.36
MPL P40238 6/20 0.33
GPR119 Q8TDV5 1/20 0.33
TOP2A P11388 1/20 0.33
HSD11B1 P28845 1/20 0.32
S1PR1 P21453 3/20 0.32
S1PR5 Q9H228 2/20 0.32
PLA2G6 O60733 2/20 0.32
PLA2G4A P47712 1/20 0.32
FAAH O00519 1/20 0.32
PRKCG P05129 1/20 0.32
PRKCB P05771 1/20 0.32
PRKCA P17252 1/20 0.32
PRKCH P24723 1/20 0.32
PRKCE Q02156 1/20 0.32
PRKCQ Q04759 1/20 0.32
PRKCD Q05655 1/20 0.32
S1PR3 Q99500 2/20 0.31
S1PR4 O95977 1/20 0.31
RARA P10276 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12376120 0.86 MAOA (0.33) GPR119
SCHEMBL12376118 0.84 SPHK1 (0.40)
SCHEMBL12376011 0.83 RARB (0.35) RARBS1PR1S1PR5PLA2G6PLA2G4A
SCHEMBL12376109 0.83 CYP2C9 (0.37) GPR119
SCHEMBL12376017 0.83 GPR119 (0.35) GPR119
SCHEMBL12376062 0.82 KCNJ1 (0.38) MPL
SCHEMBL12376111 0.82 GPR119 (0.38) MPLGPR119
SCHEMBL12375894 0.82 RARB (0.41) RARBMPLHSD11B1S1PR1S1PR5
SCHEMBL12375895 0.81 RARB (0.40) RARBMPLHSD11B1S1PR1S1PR5
SCHEMBL12376016 0.80 RORC (0.33) GPR119S1PR1S1PR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110193021-A1 COMPOUND HAVING HYDROCOUMARIN SKELETON, LIQUID CRYSTAL COMPOSTITION, AND LIQUID CRYSTAL DISPLAY DEVICE CHISSO CORPORATION (JP) 2011-08-11 US disclosed
US-7951305-B2 Compound having hydrocoumarin skeleton, liquid crystal composition, and liquid crystal display device CHISSO CORPORATION (JP) 2011-05-31 US disclosed
US-20090267026-A1 COMPOUND HAVING HYDROCOUMARIN SKELETON, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE JNC PETROCHEMICAL CORPORATION (JP) 2009-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090267026-A1 COMPOUND HAVING HYDROCOUMARIN SKELETON, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE HCN2, PIEZO1, TRPV4 RARB 2217/4885MPL 4076/4885GPR119 3698/4885
US-20110193021-A1 COMPOUND HAVING HYDROCOUMARIN SKELETON, LIQUID CRYSTAL COMPOSTITION, AND LIQUID CRYSTAL DISPLAY DEVICE PIEZO1, HCN2, HCN1 RARB 3578/4885MPL 3919/4885GPR119 3463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.